Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

aiProteins_Final_logo300
10/04/2023

AI Proteins Announces the Appointment of Dr. Robert Stein to its Scientific Advisory Board

READ MORE
CareVet-Logo-New
09/26/2023

CareVet Partners with Blendvet™ & Hill’s Pet Nutrition to Launch Groundbreaking DEIB Initiative

READ MORE
NextRNA-Logo-FullColor-400
09/26/2023

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

READ MORE
wugen-logo-400
09/09/2023

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

READ MORE
Logo-Geneoscopy-400
09/06/2023

Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

READ MORE
C4-logo-400
09/05/2023

C4 Therapeutics Announces Chief Financial Officer Succession

READ MORE
wugen-logo-400
08/15/2023

Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

READ MORE
C4-logo-400
08/08/2023

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

READ MORE
aiProteins_Final_logo300
08/08/2023

AI Proteins Strengthens Leadership with Appointment of Noah D. Beerman as Chief Executive Officer and Industry Leader Mark J. Alles as Chairman of the Board of Directors

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300